throbber
Case 3:13-cv-06560-JAP-TJB Document 1 Filed 10/30/13 Page 1 of 9 PageID: 1
`
`George F. Pappas (gpappas@cov.com)
`Jeffrey B. Elikan (jelikan@cov.com)
`Benjamin C. Block (bblock@cov.com)
`Eric R. Sonnenschein
`(esonnenschein@cov.com)
`Michael N. Kennedy (mkennedy@cov.com)
`COVINGTON & BURLING LLP
`1201 Pennsylvania Ave., NW
`Washington, DC 20004-2401
`(202) 662-6000
`
`Counsel for Plaintiff
`Warner Chilcott Company, LLC
`
`
`William J. O’Shaughnessy
`(woshaughnessy@mccarter.com)
`Cynthia S. Betz (cbetz@mccarter.com)
`MCCARTER & ENGLISH, LLP
`Four Gateway Center
`100 Mulberry St.
`Newark, NJ 07102
`Tel: (973) 622-4444
`Fax: (973) 624-7070
`
`
`Dominick A. Conde (dconde@fchs.com)
`Jason A. Leonard (jleonard@fchs.com)
`FITZPATRICK, CELLA, HARPER
`& SCINTO
`1290 Avenue of the Americas
`New York, NY 10104
`Tel: (212) 218-2100
`Fax: (212) 218-2200
`
`
`
`
`
`UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF NEW JERSEY
`
`
`
`WARNER CHILCOTT COMPANY, LLC,
`
`
`
`
`
`
`
`Plaintiff,
`
`
`
`
`
`
`
`C. A. No.
`
`
`
`
`
`Defendants.
`
`COMPLAINT FOR PATENT INFRINGEMENT
`
`
`
`
`
`v.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`MYLAN INC., MYLAN PHARMACEUTICALS
`INC. and FAMY CARE LTD.,
`
`Mylan v. Warner Chilcott IPR2015-00682
`WC Ex. 2028, Pg. 1
`
`

`
`Case 3:13-cv-06560-JAP-TJB Document 1 Filed 10/30/13 Page 2 of 9 PageID: 2
`
`
`
`Plaintiff Warner Chilcott Company, LLC by its undersigned attorneys, brings this
`
`action against Defendants Mylan Inc., Mylan Pharmaceuticals Inc., and Famy Care Ltd.
`
`(collectively “Defendants”), and hereby alleges as follows:
`
`THE PARTIES
`
`1.
`
`Plaintiff Warner Chilcott Company, LLC (“Warner Chilcott”) is a limited
`
`liability company organized and existing under the laws of Puerto Rico, having offices at Union
`
`St., Road 195, Km 1.1, Fajardo, Puerto Rico.
`
`2.
`
`Upon information and belief, Defendant Mylan Inc. is a corporation
`
`organized and existing under the laws of Pennsylvania, having an office and place of business at
`
`1500 Corporate Drive, Canonsburg, Pennsylvania 15317.
`
`3.
`
`Upon information and belief, Defendant Mylan Pharmaceuticals Inc.
`
`(“Mylan Pharms”) is a corporation organized and existing under the laws of West Virginia,
`
`having an office and place of business at 781 Chestnut Ridge Road, Morgantown, West Virginia
`
`26505. Upon information and belief, Mylan Pharms is a wholly-owned subsidiary of Mylan Inc.
`
`4.
`
`Upon information and belief, Defendant Famy Care Ltd. (“Famy Care”) is
`
`organized and exists under the laws of the Republic of India and has a principal place of business
`
`at 3rd Floor, Brady House, 12/14, Veer Nariman Road, Fort, Mumbai – 400 001, India.
`
`5.
`
`Upon information and belief, Mylan Inc. is doing business in New Jersey.
`
`Upon information and belief Mylan Inc. is registered to do business in New Jersey. Mylan Inc.,
`
`directly, or through its subsidiaries, including Mylan Pharms, has engaged in continuous and
`
`systematic contacts with New Jersey, and purposefully availed itself of this forum by, among
`
`other things, shipping, using, offering to sell, selling, or causing others to use, offer to sell, or sell
`
`
`
`2
`
`Mylan v. Warner Chilcott IPR2015-00682
`WC Ex. 2028, Pg. 2
`
`

`
`Case 3:13-cv-06560-JAP-TJB Document 1 Filed 10/30/13 Page 3 of 9 PageID: 3
`
`
`
`pharmaceutical products in New Jersey and deriving substantial revenue from such activities,
`
`and by filing counterclaims in New Jersey.
`
`6.
`
`Upon information and belief, Mylan Pharms is doing business in New
`
`Jersey. Upon information and belief Mylan Pharms is registered to do business in New Jersey.
`
`Mylan Pharms has engaged in continuous and systematic contacts with New Jersey, and
`
`purposefully availed itself of this forum by, among other things, shipping, using, offering to sell,
`
`selling, or causing others to use, offer to sell, or sell pharmaceutical products in New Jersey and
`
`deriving substantial revenue from such activities, and by filing counterclaims in New Jersey.
`
`7.
`
`Upon information and belief, Famy Care has engaged in continuous and
`
`systematic contacts with the United States by, among others things, on or about August 7, 2008,
`
`entering into an agreement with Mylan Inc. to file ANDAs for generic contraceptive products
`
`and to supply such products to customers in the United States.
`
`JURISDICTION AND VENUE
`
`8.
`
`This is an action for patent infringement arising under the patent laws of
`
`the United States, Title 35, United States Code. This Court has subject matter jurisdiction over
`
`this action based on 28 U.S.C. §§ 1331 and 1338(a).
`
`9.
`
`This Court has personal jurisdiction over Mylan Inc. and Mylan Pharms,
`
`because, inter alia, Mylan Inc. and Mylan Pharms have purposefully availed themselves of the
`
`rights and benefits of New Jersey law. Upon information and belief, Defendants Mylan Inc. and
`
`Mylan Pharms engage in the sale of a range of generic pharmaceutical products within the
`
`United States generally and New Jersey specifically.
`
`10.
`
`This Court has personal jurisdiction over Famy Care at least under Federal
`
`Rule of Civil Procedure 4(k)(2).
`
`
`
`3
`
`Mylan v. Warner Chilcott IPR2015-00682
`WC Ex. 2028, Pg. 3
`
`

`
`Case 3:13-cv-06560-JAP-TJB Document 1 Filed 10/30/13 Page 4 of 9 PageID: 4
`
`
`
`11.
`
`Venue is proper in this Court under 28 U.S.C. §§ 1391(b) and (c), and 28
`
`U.S.C. § 1400(b).
`
`BACKGROUND
`
`12. Warner Chilcott is the holder of New Drug Application (“NDA”) No. 22-
`
`501, for Lo Loestrin® Fe, which contains the active ingredients norethindrone acetate and ethinyl
`
`estradiol. Lo Loestrin® Fe was approved by the FDA on October 21, 2010 and is indicated for
`
`the prevention of pregnancy in women who elect to use it as a method of contraception. Lo
`
`Loestrin® Fe is sold as a 28-day oral contraceptive regimen which includes 24 active tablets
`
`comprising 1 mg norethindrone acetate and 0.01 mg ethinyl estradiol, 2 active tablets comprising
`
`0.01 mg ethinyl estradiol, followed by 2 ferrous fumarate tablets (placebo).
`
`13.
`
`U.S. Patent No. 7,704,984 (“the ’984 patent”) entitled “Extended Estrogen
`
`Dosing Contraceptive Regimen” lawfully issued from the United States Patent and Trademark
`
`Office on April 27, 2010. A copy of the ’984 patent is attached as Exhibit A.
`
`14. Warner Chilcott is the sole owner of the ’984 patent.
`
`15.
`
`The ’984 patent claims, inter alia, a method of female contraception which
`
`comprises administering (a) a first composition containing a progestin in an amount equivalent to
`
`about 0.3 to about 1.5 mg norethindrone acetate wherein the progestin is selected from
`
`norethindrone acetate or norethindrone and 5 to 15 mcg of ethinyl estradiol for 24 days, (b) a
`
`second composition containing 5 to 15 mcg of ethinyl estradiol and substantially free of a
`
`progestin for 2 days, and (c) a third composition that is a placebo, wherein the sequential
`
`administration of the first composition, the second composition and the third composition, is
`
`performed on a daily basis over a 28 day cycle.
`
`
`
`4
`
`Mylan v. Warner Chilcott IPR2015-00682
`WC Ex. 2028, Pg. 4
`
`

`
`Case 3:13-cv-06560-JAP-TJB Document 1 Filed 10/30/13 Page 5 of 9 PageID: 5
`
`
`
`16.
`
`The ’984 patent covers the use of Lo Loestrin® Fe in accordance with the
`
`respective labeling approved by the FDA and is listed in the FDA Approved Drug Products with
`
`Therapeutic Equivalence Evaluations (“the Orange Book”) for that product.
`
`17.
`
`Upon information and belief, Famy Care, together with its U.S. agent,
`
`Mylan Pharms, submitted to the FDA an Abbreviated New Drug Application (“ANDA”) filed
`
`under 21 U.S.C. § 355(j), to obtain approval to engage in the commercial manufacture, use, or
`
`sale of a generic version of Lo Loestrin® Fe (the “Defendants’ ANDA Product”) prior to the
`
`expiration of the ’984 patent.
`
`18.
`
`Upon information and belief, Defendants’ ANDA directed to its proposed
`
`generic Lo Loestrin® Fe product has been assigned No. 20-5049.
`
`19.
`
`Upon information and belief, the composition that is the subject of
`
`Defendants’ ANDA is directed to 24 tablets containing 1 mg norethindrone acetate and 0.01 mg
`
`ethinyl estradiol, 2 tablets containing 0.01 mg ethinyl estradiol and 2 tablets containing ferrous
`
`fumarate (placebo).
`
`COUNT I
`CLAIM FOR INFRINGEMENT OF THE ’984 PATENT
`
`Upon information and belief, Defendants’ ANDA was submitted with a
`
`20.
`
`certification pursuant to 21 U.S.C. § 355(j)(2)(A)(vii)(IV) of the Federal Food, Drug and
`
`Cosmetic Act that the ’984 patent is purportedly invalid, unenforceable, and/or will not be
`
`infringed by the manufacture, use or sale of Defendants’ ANDA Product.
`
`21.
`
`Upon information and belief, Defendants sent notice of that certification to
`
`Warner Chilcott on or about September 19, 2013. Warner Chilcott received Defendants’ notice
`
`letter on or about September 20, 2013.
`
`
`
`5
`
`Mylan v. Warner Chilcott IPR2015-00682
`WC Ex. 2028, Pg. 5
`
`

`
`Case 3:13-cv-06560-JAP-TJB Document 1 Filed 10/30/13 Page 6 of 9 PageID: 6
`
`
`
`22.
`
`By filing the Defendants’ ANDA under 21 U.S.C. § 355(j) for the purpose
`
`of obtaining approval to engage in the manufacture, use or sale of their ANDA Product before
`
`the expiration of the ’984 patent, Famy Care and its U.S. agent, Mylan Pharms, have committed
`
`an act of infringement pursuant to 35 U.S.C. § 271(e)(2)(A). Further, the manufacture, use or
`
`sale of Defendants’ ANDA Product will also infringe one or more claims of the ’984 patent.
`
`23.
`
`Upon approval of Defendants’ ANDA, Defendants will actively induce
`
`and/or contribute to infringement of the ’984 patent.
`
`24.
`
`Upon information and belief, the acts of Mylan Pharms and Famy Care
`
`complained of herein were done and are being done at the direction of, with the authorization of,
`
`and/or with the cooperation, participation and assistance of, and at least in part for the benefit of,
`
`Mylan Inc.
`
`25. Warner Chilcott is entitled to relief provided by 35 U.S.C. § 271(e)(4),
`
`including an order from this Court that the effective date of the approval of Defendants’ ANDA
`
`be a date that is not earlier than the expiration date of the ’984 patent, or any later expiration of
`
`exclusivity to which Warner Chilcott is or becomes entitled.
`
`26.
`
`This is an exceptional case, and Warner Chilcott is entitled to its costs and
`
`reasonable attorney fees.
`
`PRAYER FOR RELIEF
`
`WHEREFORE, Plaintiff respectfully requests the following relief:
`
`(a)
`
`Judgment that Defendants Mylan Inc., Mylan Pharmaceuticals Inc., and
`
`Famy Care Ltd. have infringed one or more claims of the ’984 patent by submitting ANDA No.
`
`20-5049;
`
`
`
`6
`
`Mylan v. Warner Chilcott IPR2015-00682
`WC Ex. 2028, Pg. 6
`
`

`
`Case 3:13-cv-06560-JAP-TJB Document 1 Filed 10/30/13 Page 7 of 9 PageID: 7
`
`
`
`(b)
`
`A permanent injunction be issued restraining and enjoining Defendants
`
`Mylan Inc., Mylan Pharmaceuticals Inc., and Famy Care Ltd., their officers, agents, attorneys,
`
`and employees, and those acting in privity or concert with them, and their successors and
`
`assigns, from engaging in the commercial manufacture, use, offer to sell, or sale within the
`
`United States, or importation into the United States, of compositions that would infringe, induce
`
`infringement and/or contribute to infringement of the ’984 patent;
`
`(c)
`
`An order that the effective date of any approval of Defendants’ ANDA
`
`No. 20-5049, be a date that is not earlier than the expiration of the ’984 patent, or any later
`
`expirations of exclusivity to which Plaintiff is or becomes entitled;
`
`(d)
`
`Declaring this to be an exceptional case and awarding Plaintiff its attorney
`
`fees under 35 U.S.C. § 285; and
`
`(e)
`
`Such other and further relief as the Court may deem just and proper.
`
`
`
`7
`
`Mylan v. Warner Chilcott IPR2015-00682
`WC Ex. 2028, Pg. 7
`
`

`
`Case 3:13-cv-06560-JAP-TJB Document 1 Filed 10/30/13 Page 8 of 9 PageID: 8
`
`
`
`
`
`
`
`Respectfully submitted,
`
`
`
`
`
` /s/ William J. O’Shaughnessy
`William J. O’Shaughnessy
`(woshaughnessy@mccarter.com)
`Cynthia S. Betz (cbetz@mccarter.com)
`MCCARTER & ENGLISH, LLP
`Four Gateway Center
`100 Mulberry St.
`Newark, NJ 07102
`Tel: (973) 622-4444
`Fax: (973) 624-7070
`
`
`Counsel for Plaintiff
`Warner Chilcott Company, LLC
`
`
`
`
`
`
`October 30, 2013
`
`
`
`
`
`George F. Pappas (gpappas@cov.com)
`Jeffrey B. Elikan (jelikan@cov.com)
`Benjamin C. Block (bblock@cov.com)
`Eric R. Sonnenschein
`(esonnenschein@cov.com)
`Michael N. Kennedy (mkennedy@cov.com)
`COVINGTON & BURLING LLP
`1201 Pennsylvania Ave., NW
`Washington, DC 20004-2401
`(202) 662-6000
`Dominick A. Conde (dconde@fchs.com)
`Jason A. Leonard (jleonard@fchs.com)
`FITZPATRICK, CELLA, HARPER
`& SCINTO
`1290 Avenue of the Americas
`New York, NY 10104
`Tel: (212) 218-2100
`Fax: (212) 218-2200
`
`
`
`
`8
`
`Mylan v. Warner Chilcott IPR2015-00682
`WC Ex. 2028, Pg. 8
`
`

`
`Case 3:13-cv-06560-JAP-TJB Document 1 Filed 10/30/13 Page 9 of 9 PageID: 9
`
`
`
`
`
` CERTIFICATION PURSUANT TO L. CIV. R. 11.2
`
`Plaintiff, by its undersigned counsel, hereby certifies pursuant to L. Civ. R. 11.2 that the
`
`matters in controversy in the instant action overlap with the subject matter of two other pending
`
`actions in this Court regarding the same patent (U.S. Patent No. 7,704,984) and the same
`
`product, Lo Loestrin® Fe. The first of these two other actions was filed on September 1, 2011
`
`and is captioned Warner Chilcott Company, LLC v. Lupin Ltd. et al., 11-cv-05048-JAP-TJB.
`
`The second of these two other actions was filed on May 16, 2012 and is captioned Warner
`
`Chilcott Company, LLC v. Amneal Pharmaceuticals, LLC et al., 12-cv-02928-JAP-TJB. The
`
`Court held a joint bench trial in these two actions between October 7, 2013 and October 17,
`
`2013.
`
`Respectfully submitted,
`
`
`
`
`
` /s/ William J. O’Shaughnessy
`William J. O’Shaughnessy
`(woshaughnessy@mccarter.com)
`Cynthia S. Betz (cbetz@mccarter.com)
`MCCARTER & ENGLISH, LLP
`Four Gateway Center
`100 Mulberry St.
`Newark, NJ 07102
`Tel: (973) 622-4444
`Fax: (973) 624-7070
`
`
`Counsel for Plaintiff
`Warner Chilcott Company, LLC
`
`
`
`October 30, 2013
`
`
`
`George F. Pappas (gpappas@cov.com)
`Jeffrey B. Elikan (jelikan@cov.com)
`Benjamin C. Block (bblock@cov.com)
`Eric R. Sonnenschein
`(esonnenschein@cov.com)
`Michael N. Kennedy (mkennedy@cov.com)
`COVINGTON & BURLING LLP
`1201 Pennsylvania Ave., NW
`Washington, DC 20004-2401
`(202) 662-6000
`Dominick A. Conde (dconde@fchs.com)
`Jason A. Leonard (jleonard@fchs.com)
`FITZPATRICK, CELLA, HARPER
`& SCINTO
`1290 Avenue of the Americas
`New York, NY 10104
`Tel: (212) 218-2100
`Fax: (212) 218-2200
`
`
`
`
`
`
`
`
`
`Mylan v. Warner Chilcott IPR2015-00682
`WC Ex. 2028, Pg. 9
`
`

`
`Case 3:13-cv-06560-JAP-TJB Document 1-1 Filed 10/30/13 Page 1 of 5 PageID: 10
`
`
`Exhibit A
`
`Mylan v. Warner Chilcott IPR2015-00682
`WC Ex. 2028, Pg. 10
`
`

`
`Case 3:13-cv-06560-JAP-TJB Document 1-1 Filed 10/30/13 Page 2 of 5 PageID: 11
`
`Mylan v. Warner Chilcott IPR2015-00682
`WC Ex. 2028, Pg. 11
`
`

`
`Case 3:13-cv-06560-JAP-TJB Document 1-1 Filed 10/30/13 Page 3 of 5 PageID: 12
`
`Mylan v. Warner Chilcott IPR2015-00682
`WC Ex. 2028, Pg. 12
`
`

`
`Case 3:13-cv-06560-JAP-TJB Document 1-1 Filed 10/30/13 Page 4 of 5 PageID: 13
`
`Mylan v. Warner Chilcott IPR2015-00682
`WC Ex. 2028, Pg. 13
`
`

`
`Case 3:13-cv-06560-JAP-TJB Document 1-1 Filed 10/30/13 Page 5 of 5 PageID: 14
`
`Mylan v. Warner Chilcott IPR2015-00682
`WC Ex. 2028, Pg. 14
`
`

`
`-6  5HY 

`
`Case 3:13-cv-06560-JAP-TJB Document 1-2 Filed 10/30/13 Page 1 of 2 PageID: 15
` CIVIL COVER SHEET
`7KH -6  FLYLO FRYHU VKHHW DQG WKH LQIRUPDWLRQ FRQWDLQHG KHUHLQ QHLWKHU UHSODFH QRU VXSSOHPHQW WKH ILOLQJ DQG VHUYLFH RI SOHDGLQJV RU RWKHU SDSHUV DV UHTXLUHG E\ ODZ H[FHSW DV
`SURYLGHG E\ ORFDO UXOHV RI FRXUW 7KLV IRUP DSSURYHG E\ WKH -XGLFLDO &RQIHUHQFH RI WKH 8QLWHG 6WDWHV LQ 6HSWHPEHU  LV UHTXLUHG IRU WKH XVH RI WKH &OHUN RI &RXUW IRU WKH
`SXUSRVH RI LQLWLDWLQJ WKH FLYLO GRFNHW VKHHW 6(( ,16758&7,216 21 1(;7 3$*( 2) 7+,6 )250

`
`I. (a) PLAINTIFFS
`WARNER CHILCOTT COMPANY, LLC
`
`DEFENDANTS
`MYLAN INC., MYLAN PHARMACEUTICALS INC. and FAMY CARE
`LTD.
`
`(b) &RXQW\ RI 5HVLGHQFH RI )LUVW /LVWHG 3ODLQWLII
`
`Fajardo, Puerto Rico
` (;&(37 ,1 86 3/$,17,)) &$6(6

`
`&RXQW\ RI 5HVLGHQFH RI )LUVW /LVWHG 'HIHQGDQW
`
`Canonsburg, PA
` ,1 86 3/$,17,)) &$6(6 21/<

`
`(c) $WWRUQH\V )LUP 1DPH $GGUHVV (PDLO DQG 7HOHSKRQH 1XPEHU

`William J. O’Shaughnessy and Cynthia S. Betz, McCarter & English,
`LLP, 100 Mulberry Street, 4 Gateway Center, Newark, NJ 07102,
`973-622-4444, woshaughnessy@mccarter.com, cbetz@mccarter.com
`
`127(
`
`,1 /$1' &21'(01$7,21 &$6(6 86( 7+( /2&$7,21 2)
`7+( 75$&7 2) /$1' ,192/9('
`
` $WWRUQH\V ,I .QRZQ

`
`II. BASIS OF JURISDICTION 3ODFH DQ ³;´ LQ 2QH %R[ 2QO\

`
`u  86 *RYHUQPHQW
`3ODLQWLII
`
`u  )HGHUDO 4XHVWLRQ
` 86 *RYHUQPHQW 1RW D 3DUW\

`
`III. CITIZENSHIP OF PRINCIPAL PARTIES 3ODFH DQ ³;´ LQ 2QH %R[ IRU 3ODLQWLII
` )RU 'LYHUVLW\ &DVHV 2QO\

` DQG 2QH %R[ IRU 'HIHQGDQW

` PTF DEF
` PTF
` DEF
`u 
`u 
`u 
`u 
`,QFRUSRUDWHG RU 3ULQFLSDO 3ODFH
`&LWL]HQ RI 7KLV 6WDWH
` RI %XVLQHVV ,Q 7KLV 6WDWH
`
`u  86 *RYHUQPHQW
`'HIHQGDQW
`
`u  'LYHUVLW\
` ,QGLFDWH &LWL]HQVKLS RI 3DUWLHV LQ ,WHP ,,,

`
`&LWL]HQ RI $QRWKHU 6WDWH
`
`u 
`
`u 
`
`,QFRUSRUDWHG DQG 3ULQFLSDO 3ODFH
`RI %XVLQHVV ,Q $QRWKHU 6WDWH
`
`u 
`
`u 
`
`IV. NATURE OF SUIT 3ODFH DQ ³;´ LQ 2QH %R[ 2QO\

`CONTRACT
`TORTS
`
`&LWL]HQ RU 6XEMHFW RI D
` )RUHLJQ &RXQWU\
`
`u 
`
`u 
`
`)RUHLJQ 1DWLRQ
`
`u 
`
`u 
`
`FORFEITURE/PENALTY
`
`BANKRUPTCY
`
`OTHER STATUTES
`
`u  ,QVXUDQFH
` PERSONAL INJURY
` PERSONAL INJURY
`u  3HUVRQDO ,QMXU\ 
`u  $LUSODQH
`u  0DULQH
`u  $LUSODQH 3URGXFW
`u  0LOOHU $FW
` 3URGXFW /LDELOLW\
`u  +HDOWK &DUH
`u  1HJRWLDEOH ,QVWUXPHQW
` /LDELOLW\
`u  5HFRYHU\ RI 2YHUSD\PHQW u  $VVDXOW /LEHO
` 3KDUPDFHXWLFDO
` 3HUVRQDO ,QMXU\
` (QIRUFHPHQW RI -XGJPHQW
` 6ODQGHU
`u  0HGLFDUH $FW
`u  )HGHUDO (PSOR\HUV¶
` 3URGXFW /LDELOLW\
`u  $VEHVWRV 3HUVRQDO
`u  5HFRYHU\ RI 'HIDXOWHG
` /LDELOLW\
`u  0DULQH
` ,QMXU\ 3URGXFW
` 6WXGHQW /RDQV
`u  0DULQH 3URGXFW
` /LDELOLW\
` ([FOXGHV 9HWHUDQV

`LABOR
` PERSONAL PROPERTY u  )DLU /DERU 6WDQGDUGV
`u  5HFRYHU\ RI 2YHUSD\PHQW
` /LDELOLW\
`u  2WKHU )UDXG
`u  0RWRU 9HKLFOH
` $FW
` RI 9HWHUDQ¶V %HQHILWV
`u  7UXWK LQ /HQGLQJ
`u  /DERU0DQDJHPHQW
`u  6WRFNKROGHUV¶ 6XLWV
`u  0RWRU 9HKLFOH
`u  2WKHU 3HUVRQDO
`u  2WKHU &RQWUDFW
` 5HODWLRQV
` 3URGXFW /LDELOLW\
`u  5DLOZD\ /DERU $FW
`u  &RQWUDFW 3URGXFW /LDELOLW\ u  2WKHU 3HUVRQDO
` 3URSHUW\ 'DPDJH
`u  3URSHUW\ 'DPDJH
`u  )DPLO\ DQG 0HGLFDO
`u  )UDQFKLVH
` ,QMXU\
`u  3HUVRQDO ,QMXU\ 
` 3URGXFW /LDELOLW\
` /HDYH $FW
`u  2WKHU /DERU /LWLJDWLRQ
` 0HGLFDO 0DOSUDFWLFH
` PRISONER PETITIONS u  (PSOR\HH 5HWLUHPHQW
` CIVIL RIGHTS
`u  2WKHU &LYLO 5LJKWV
` ,QFRPH 6HFXULW\ $FW
`Habeas Corpus:
`u  $OLHQ 'HWDLQHH
`u  9RWLQJ
`u  0RWLRQV WR 9DFDWH
`u  (PSOR\PHQW
`u  +RXVLQJ
` 6HQWHQFH
`u  *HQHUDO
` $FFRPPRGDWLRQV
`u  $PHU Z'LVDELOLWLHV  u  'HDWK 3HQDOW\
` (PSOR\PHQW
`Other:
`u  $PHU Z'LVDELOLWLHV  u  0DQGDPXV 2WKHU
`u  &LYLO 5LJKWV
` 2WKHU
`u  (GXFDWLRQ
`u  3ULVRQ &RQGLWLRQ
`u  &LYLO 'HWDLQHH 
` &RQGLWLRQV RI
` &RQILQHPHQW
`
`u  $SSHDO  86& 
`u  'UXJ 5HODWHG 6HL]XUH
` RI 3URSHUW\  86&  u  :LWKGUDZDO
`u  2WKHU
`  86& 
`
`u  )DOVH &ODLPV $FW
`u  6WDWH 5HDSSRUWLRQPHQW
`u  $QWLWUXVW
`u  %DQNV DQG %DQNLQJ
`u  &RPPHUFH
`u  'HSRUWDWLRQ
`u  5DFNHWHHU ,QIOXHQFHG DQG
` &RUUXSW 2UJDQL]DWLRQV
`u  &RQVXPHU &UHGLW
`u  &DEOH6DW 79
`u  6HFXULWLHV&RPPRGLWLHV
` ([FKDQJH
`u  2WKHU 6WDWXWRU\ $FWLRQV
`u  $JULFXOWXUDO $FWV
`u  (QYLURQPHQWDO 0DWWHUV
`u  )UHHGRP RI ,QIRUPDWLRQ
` $FW
`u  $UELWUDWLRQ
`u  $GPLQLVWUDWLYH 3URFHGXUH
` $FW5HYLHZ RU $SSHDO RI
` $JHQF\ 'HFLVLRQ
`u  &RQVWLWXWLRQDOLW\ RI
` 6WDWH 6WDWXWHV
`
`PROPERTY RIGHTS
`u  &RS\ULJKWV
`u  3DWHQW
`u  7UDGHPDUN
`
`SOCIAL SECURITY
`u  +,$ II

`u  %ODFN /XQJ 

`u  ',:&',::  J

`u  66,' 7LWOH ;9,
`u  56,  J

`
`FEDERAL TAX SUITS
`u  7D[HV 86 3ODLQWLII
` RU 'HIHQGDQW

`u  ,56²7KLUG 3DUW\
`  86& 
`
`IMMIGRATION
`u  1DWXUDOL]DWLRQ $SSOLFDWLRQ
`u  2WKHU ,PPLJUDWLRQ
` $FWLRQV
`
` REAL PROPERTY
`u  /DQG &RQGHPQDWLRQ
`u  )RUHFORVXUH
`u  5HQW /HDVH (MHFWPHQW
`u  7RUWV WR /DQG
`u  7RUW 3URGXFW /LDELOLW\
`u  $OO 2WKHU 5HDO 3URSHUW\
`
`V. ORIGIN 3ODFH DQ ³;´ LQ 2QH %R[ 2QO\

`u  2ULJLQDO
`u  5HPRYHG IURP
`3URFHHGLQJ
`6WDWH &RXUW
`
`u  5HPDQGHG IURP
`$SSHOODWH &RXUW
`
`u  5HLQVWDWHG RU
`5HRSHQHG
`
`u  0XOWLGLVWULFW
`/LWLJDWLRQ
`
`u  7UDQVIHUUHG IURP
`$QRWKHU 'LVWULFW
` VSHFLI\

`&LWH WKH 86 &LYLO 6WDWXWH XQGHU ZKLFK \RX DUH ILOLQJ (Do not cite jurisdictional statutes unless diversity

`35 USC 271
`ULHI GHVFULSWLRQ RI FDXVH
`Patent Infringement
`u &+(&. ,) 7+,6 ,6 $ CLASS ACTION
`81'(5 58/(  )5&Y3
`
`DEMAND $
`
`&+(&. <(6 RQO\ LI GHPDQGHG LQ FRPSODLQW
`u <HV
`u 1R
`
`JURY DEMAND:
`
` 6HH LQVWUXFWLRQV

`
`-8'*(
`
`Hon. Joel A. Pisano, USDJ
`
`'2&.(7 180%(5
`
`11-cv-5048; 12-cv-2928
`
`6,*1$785( 2) $77251(< 2) 5(&25'
`/s/ William J. O'Shaughnessy
`
` %
`
`VI. CAUSE OF ACTION
`
`VII. REQUESTED IN
` COMPLAINT:
`
`VIII. RELATED CASE(S)
` IF ANY
`
`'$7(
`10/30/2013
`FOR OFFICE USE ONLY
`
`5(&(,37 
`
`$02817
`
`$33/<,1* ,)3
`
`-8'*(
`
`0$* -8'*(
`
`Mylan v. Warner Chilcott IPR2015-00682
`WC Ex. 2028, Pg. 1
`
`

`
`-6  5HYHUVH 5HY 

`
`Case 3:13-cv-06560-JAP-TJB Document 1-2 Filed 10/30/13 Page 2 of 2 PageID: 16
`
`INSTRUCTIONS FOR ATTORNEYS COMPLETING CIVIL COVER SHEET FORM JS 44
`
`$XWKRULW\ )RU &LYLO &RYHU 6KHHW
`
`7KH -6  FLYLO FRYHU VKHHW DQG WKH LQIRUPDWLRQ FRQWDLQHG KHUHLQ QHLWKHU UHSODFHV QRU VXSSOHPHQWV WKH ILOLQJV DQG VHUYLFH RI SOHDGLQJ RU RWKHU SDSHUV DV
`UHTXLUHG E\ ODZ H[FHSW DV SURYLGHG E\ ORFDO UXOHV RI FRXUW 7KLV IRUP DSSURYHG E\ WKH -XGLFLDO &RQIHUHQFH RI WKH 8QLWHG 6WDWHV LQ 6HSWHPEHU  LV
`UHTXLUHG IRU WKH XVH RI WKH &OHUN RI &RXUW IRU WKH SXUSRVH RI LQLWLDWLQJ WKH FLYLO GRFNHW VKHHW &RQVHTXHQWO\ D FLYLO FRYHU VKHHW LV VXEPLWWHG WR WKH &OHUN RI
`&RXUW IRU HDFK FLYLO FRPSODLQW ILOHG 7KH DWWRUQH\ ILOLQJ D FDVH VKRXOG FRPSOHWH WKH IRUP DV IROORZV
`
`I.(a) Plaintiffs-Defendants. (QWHU QDPHV ODVW ILUVW PLGGOH LQLWLDO
RI SODLQWLII DQG GHIHQGDQW ,I WKH SODLQWLII RU GHIHQGDQW LV D JRYHUQPHQW DJHQF\ XVH
`RQO\ WKH IXOO QDPH RU VWDQGDUG DEEUHYLDWLRQV ,I WKH SODLQWLII RU GHIHQGDQW LV DQ RIILFLDO ZLWKLQ D JRYHUQPHQW DJHQF\ LGHQWLI\ ILUVW WKH DJHQF\ DQG
`WKHQ WKH RIILFLDO JLYLQJ ERWK QDPH DQG WLWOH
` (b) County of Residence. )RU HDFK FLYLO FDVH ILOHG H[FHSW 86 SODLQWLII FDVHV HQWHU WKH QDPH RI WKH FRXQW\ ZKHUH WKH ILUVW OLVWHG SODLQWLII UHVLGHV DW WKH
`WLPH RI ILOLQJ ,Q 86 SODLQWLII FDVHV HQWHU WKH QDPH RI WKH FRXQW\ LQ ZKLFK WKH ILUVW OLVWHG GHIHQGDQW UHVLGHV DW WKH WLPH RI ILOLQJ 127( ,Q ODQG
`FRQGHPQDWLRQ FDVHV WKH FRXQW\ RI UHVLGHQFH RI WKH GHIHQGDQW LV WKH ORFDWLRQ RI WKH WUDFW RI ODQG LQYROYHG

` (c) Attorneys. (QWHU WKH ILUP QDPH DGGUHVV WHOHSKRQH QXPEHU DQG DWWRUQH\ RI UHFRUG ,I WKHUH DUH VHYHUDO DWWRUQH\V OLVW WKHP RQ DQ DWWDFKPHQW QRWLQJ
`LQ WKLV VHFWLRQ  VHH DWWDFKPHQW

`
`II.
`
`Jurisdiction. 7KH EDVLV RI MXULVGLFWLRQ LV VHW IRUWK XQGHU 5XOH  D
 )5&Y3 ZKLFK UHTXLUHV WKDW MXULVGLFWLRQV EH VKRZQ LQ SOHDGLQJV 3ODFH DQ ;
`LQ RQH RI WKH ER[HV ,I WKHUH LV PRUH WKDQ RQH EDVLV RI MXULVGLFWLRQ SUHFHGHQFH LV JLYHQ LQ WKH RUGHU VKRZQ EHORZ
`8QLWHG 6WDWHV SODLQWLII 
-XULVGLFWLRQ EDVHG RQ  86&  DQG  6XLWV E\ DJHQFLHV DQG RIILFHUV RI WKH 8QLWHG 6WDWHV DUH LQFOXGHG KHUH
`8QLWHG 6WDWHV GHIHQGDQW 
:KHQ WKH SODLQWLII LV VXLQJ WKH 8QLWHG 6WDWHV LWV RIILFHUV RU DJHQFLHV SODFH DQ ; LQ WKLV ER[
`)HGHUDO TXHVWLRQ 
7KLV UHIHUV WR VXLWV XQGHU  86&  ZKHUH MXULVGLFWLRQ DULVHV XQGHU WKH &RQVWLWXWLRQ RI WKH 8QLWHG 6WDWHV DQ DPHQGPHQW
`WR WKH &RQVWLWXWLRQ DQ DFW RI &RQJUHVV RU D WUHDW\ RI WKH 8QLWHG 6WDWHV ,Q FDVHV ZKHUH WKH 86 LV D SDUW\ WKH 86 SODLQWLII RU GHIHQGDQW FRGH WDNHV
`SUHFHGHQFH DQG ER[  RU  VKRXOG EH PDUNHG
`'LYHUVLW\ RI FLWL]HQVKLS 
7KLV UHIHUV WR VXLWV XQGHU  86&  ZKHUH SDUWLHV DUH FLWL]HQV RI GLIIHUHQW VWDWHV :KHQ %R[  LV FKHFNHG WKH
`FLWL]HQVKLS RI WKH GLIIHUHQW SDUWLHV PXVW EH FKHFNHG. 6HH 6HFWLRQ ,,, EHORZ; NOTE: federal question actions take precedence over diversity
`cases.

`
`III. Residence (citizenship) of Principal Parties. 7KLV VHFWLRQ RI WKH -6  LV WR EH FRPSOHWHG LI GLYHUVLW\ RI FLWL]HQVKLS ZDV LQGLFDWHG DERYH 0DUN WKLV
`VHFWLRQ IRU HDFK SULQFLSDO SDUW\
`
`IV.
`
`V.
`
`Nature of Suit. 3ODFH DQ ; LQ WKH DSSURSULDWH ER[ ,I WKH QDWXUH RI VXLW FDQQRW EH GHWHUPLQHG EH VXUH WKH FDXVH RI DFWLRQ LQ 6HFWLRQ 9, EHORZ LV
`VXIILFLHQW WR HQDEOH WKH GHSXW\ FOHUN RU WKH VWDWLVWLFDO FOHUN V
LQ WKH $GPLQLVWUDWLYH 2IILFH WR GHWHUPLQH WKH QDWXUH RI VXLW ,I WKH FDXVH ILWV PRUH WKDQ
`RQH QDWXUH RI VXLW VHOHFW WKH PRVW GHILQLWLYH
`
`Origin. 3ODFH DQ ; LQ RQH RI WKH VL[ ER[HV
`2ULJLQDO 3URFHHGLQJV 
&DVHV ZKLFK RULJLQDWH LQ WKH 8QLWHG 6WDWHV GLVWULFW FRXUWV
`5HPRYHG IURP 6WDWH &RXUW 
3URFHHGLQJV LQLWLDWHG LQ VWDWH FRXUWV PD\ EH UHPRYHG WR WKH GLVWULFW FRXUWV XQGHU 7LWOH  86& 6HFWLRQ 
`:KHQ WKH SHWLWLRQ IRU UHPRYDO LV JUDQWHG FKHFN WKLV ER[
`5HPDQGHG IURP $SSHOODWH &RXUW 
&KHFN WKLV ER[ IRU FDVHV UHPDQGHG WR WKH GLVWULFW FRXUW IRU IXUWKHU DFWLRQ 8VH WKH GDWH RI UHPDQG DV WKH ILOLQJ
`GDWH
`5HLQVWDWHG RU 5HRSHQHG 
&KHFN WKLV ER[ IRU FDVHV UHLQVWDWHG RU UHRSHQHG LQ WKH GLVWULFW FRXUW 8VH WKH UHRSHQLQJ GDWH DV WKH ILOLQJ GDWH
`7UDQVIHUUHG IURP $QRWKHU 'LVWULFW 
)RU FDVHV WUDQVIHUUHG XQGHU 7LWOH  86& 6HFWLRQ  D
 'R QRW XVH WKLV IRU ZLWKLQ GLVWULFW WUDQVIHUV RU
`PXOWLGLVWULFW OLWLJDWLRQ WUDQVIHUV
`0XOWLGLVWULFW /LWLJDWLRQ 
&KHFN WKLV ER[ ZKHQ D PXOWLGLVWULFW FDVH LV WUDQVIHUUHG LQWR WKH GLVWULFW XQGHU DXWKRULW\ RI 7LWOH  86& 6HFWLRQ 
`:KHQ WKLV ER[ LV FKHFNHG GR QRW FKHFN 
DERYH
`
`VI.
`
`Cause of Action. 5HSRUW WKH FLYLO VWDWXWH GLUHFWO\ UHODWHG WR WKH FDXVH RI DFWLRQ DQG JLYH D EULHI GHVFULSWLRQ RI WKH FDXVH Do not cite jurisdictional
`statutes unless diversity. ([DPSOH 86 &LYLO 6WDWXWH  86&  %ULHI 'HVFULSWLRQ 8QDXWKRUL]HG UHFHSWLRQ RI FDEOH VHUYLFH
`
`VII. Requested in Complaint. &ODVV $FWLRQ 3ODFH DQ ; LQ WKLV ER[ LI \RX DUH ILOLQJ D FODVV DFWLRQ XQGHU 5XOH  )5&Y3
`'HPDQG ,Q WKLV VSDFH HQWHU WKH DFWXDO GROODU DPRXQW EHLQJ GHPDQGHG RU LQGLFDWH RWKHU GHPDQG VXFK DV D SUHOLPLQDU\ LQMXQFWLRQ
`-XU\ 'HPDQG &KHFN WKH DSSURSULDWH ER[ WR LQGLFDWH ZKHWKHU RU QRW D MXU\ LV EHLQJ GHPDQGHG
`
`VIII. Related Cases. 7KLV VHFWLRQ RI WKH -6  LV XVHG WR UHIHUHQFH UHODWHG SHQGLQJ FDVHV LI DQ\ ,I WKHUH DUH UHODWHG SHQGLQJ FDVHV LQVHUW WKH GRFNHW
`QXPEHUV DQG WKH FRUUHVSRQGLQJ MXGJH QDPHV IRU VXFK FDVHV
`
`Date and Attorney Signature. 'DWH DQG VLJQ WKH FLYLO FRYHU VKHHW
`
`Mylan v. Warner Chilcott IPR2015-00682
`WC Ex. 2028, Pg. 16

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket